抗程序性死亡受体1抗体继发风湿性免疫相关不良事件及皮质类固醇对抗肿瘤反应影响的初步分析:病例系列
该多中心回顾性病例系列纳入36例癌症患者,其中12例抗PD1治疗前已有风湿病、24例新发风湿性irAE,34例风湿性irAE持续存在(中位发生时间14.5周);抗PD1客观缓解率总体69%(25/36),黑色素瘤亚组81%(21/26)。
要点
- 抗PD1相关风湿性irAE常呈慢性,需长期免疫调节治疗。
- 36例中30例使用皮质类固醇(中位10个月),14例使用改善病情抗风湿药(中位5.5个月)。
- 抗PD1客观缓解率总体69%(25/36),黑色素瘤亚组81%(21/26)。
核心结论
- 风湿性irAE常为慢性并需长期免疫调节治疗。
- 需前瞻性研究以确定既能维持长期抗肿瘤结局又能优化风湿性irAE管理的方案。
研究设计与样本
- 多中心回顾性病例系列,在三个中心回顾性审查抗PD1治疗前已有风湿病或抗PD1治疗中新发风湿性irAE的癌症患者。
- 共纳入36例癌症患者,其中抗PD1治疗前已有风湿病12例、新发风湿性irAE 24例。
- 评估患者人口学特征、治疗史、抗PD1 irAE及抗PD1反应,并分析风湿性irAE发生或预先存在、免疫调节剂使用与结局的关系。
主要发现
- 36例中34例风湿性irAE持续存在,中位发生时间14.5周。
- 24例新发风湿性irAE包括18例炎性关节炎、3例肌炎、2例风湿性多肌痛、1例筋膜炎;12例原有风湿病患者中10例出现 flare。
- 36例中30例使用皮质类固醇(中位持续时间10个月),14例使用改善病情抗风湿药(中位持续时间5.5个月)。
- 抗PD1客观缓解率总体为69%(25/36),黑色素瘤亚组为81%(21/26)。
局限性
- 原文为回顾性审查。
- 原文为病例系列。
- 原文结论指出需前瞻性研究以确定风湿性irAE的最佳管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Rheumatic immune-related adverse events (irAEs) occur in approximately 10-20% of anti-programmed death 1 (anti-PD1)-treated cancer patients. There are limited data on the natural history, optimal treatment and long-term oncological outcomes of patients with rheumatic irAEs. OBJECTIVE: The objective of the study was to describe the spectrum and natural history of rheumatic irAEs and the potential impact of rheumatic irAEs and immunomodulators on anti-PD1 tumour efficacy. METHODS: Cancer patients with pre-existing rheumatic disease before anti-PD1 therapy or de novo rheumatic irAEs on anti-PD1 therapy were retrospectively reviewed across three sites. Patient demographics, treatment history, anti-PD1 irAEs, and anti-PD1 responses were evaluated. Relationships between the development or pre-existence of rheumatic irAE, use of immunomodulatory agents and outcomes were evaluated. RESULTS: This multicenter case series describes 36 cancer patients who had rheumatic disease before anti-PD1 therapy (n = 12) or developed de novo rheumatic irAEs (n = 24). Thirty-four of the 36 patients sustained rheumatic irAEs (median time to rheumatic irAE: 14.5 weeks), including 24 de novo (18 inflammatory arthritis, three myositis, two polymyalgia rheumatica, one fasciitis) and 10 flares in 12 patients with pre-existing rheumatic disease. Corticosteroids were used in 30 of 36 patients (median duration: 10 months), and disease-modifying antirheumatic drugs were used in 14 of 36 patients (median duration: 5.5 months). The objective response rate to anti-PD1 therapy was 69% (n = 25/36) overall and 81% (n = 21/26) in the melanoma subgroup. CONCLUSIONS: Rheumatic irAEs are often chronic and require prolonged immunomodulatory therapy. Prospective studies are required to define optimal management of rheumatic irAEs that maintain long-term anticancer outcomes.
引用
- Mitchell EL, Lau PKH, Khoo C, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Eur J Cancer. 2018. PMID: 30439628. doi:10.1016/j.ejca.2018.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。